These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29939049)

  • 1. Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms.
    Streck JM; Ochalek TA; Badger GJ; Sigmon SC
    Exp Clin Psychopharmacol; 2018 Aug; 26(4):403-409. PubMed ID: 29939049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults.
    Peck KR; Ochalek TA; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2020 Mar; 208():107879. PubMed ID: 31991327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Within-subject evaluation of interim buprenorphine treatment during waitlist delays.
    Oleskowicz TN; Ochalek TA; Peck KR; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2021 Mar; 220():108532. PubMed ID: 33508690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Current Pain Status on Low-Barrier Buprenorphine Treatment Response Among Patients with Opioid Use Disorder.
    Peck KR; Ochalek TA; Streck JM; Badger GJ; Sigmon SC
    Pain Med; 2021 May; 22(5):1205-1212. PubMed ID: 33585885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
    Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST
    JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.
    Sigmon SC; C Meyer A; Hruska B; Ochalek T; Rose G; Badger GJ; Brooklyn JR; Heil SH; Higgins ST; Moore BA; Schwartz RP
    Addict Behav; 2015 Dec; 51():136-42. PubMed ID: 26256469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Worries About Discontinuing Buprenorphine Treatment: Scale Development and Clinical Correlates.
    Stein MD; Conti MT; Herman DS; Anderson BJ; Bailey GL; Noppen DV; Abrantes AM
    Am J Addict; 2019 Jul; 28(4):270-276. PubMed ID: 30993833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
    Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
    Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changes in psychosocial symptoms of opiate users over six months with buprenorphine/naloxone substitution therapy].
    Petke Z; Csorba J; Meszaros J; Vingender I; Farkas J; Demetrovics Z; Kovacs Z; Menczel Z; Pataki Z; Simor P; Havasi A; Melles K; Marvanykovi F; Racz J
    Neuropsychopharmacol Hung; 2012 Mar; 14(1):7-17. PubMed ID: 22427466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multi-site prescription opioid addiction treatment study: 18-month outcomes.
    Potter JS; Dreifuss JA; Marino EN; Provost SE; Dodd DR; Rice LS; Fitzmaurice GM; Griffin ML; Weiss RD
    J Subst Abuse Treat; 2015 Jan; 48(1):62-9. PubMed ID: 25189089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use.
    Mitchell SG; Gryczynski J; Schwartz RP; Myers CP; O'Grady KE; Olsen YK; Jaffe JH
    J Psychoactive Drugs; 2015; 47(2):149-57. PubMed ID: 25950595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of PDYN 68-bp VNTR polymorphism with sublingual buprenorphine/naloxone treatment and with opioid or alcohol use disorder: Effect on craving, depression, anxiety and age onset of first use.
    Kaya-Akyüzlü D; Özkan-Kotiloğlu S; Yalçın-Şahiner Ş; Ağtaş-Ertan E; Özgür-İlhan İ
    Eur J Pharmacol; 2022 Apr; 921():174862. PubMed ID: 35271823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DYNAMICS OF OPIOID SUBSTITUTION TREATMENTIN DIFFERENT INITIAL SUBSTANCE USER OPIOID DEPENDENT PATIENTS.
    Todadze Kh; Mosia S
    Georgian Med News; 2016 May; (254):56-61. PubMed ID: 27348169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
    Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
    JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth.
    Subramaniam GA; Warden D; Minhajuddin A; Fishman MJ; Stitzer ML; Adinoff B; Trivedi M; Weiss R; Potter J; Poole SA; Woody GE
    J Am Acad Child Adolesc Psychiatry; 2011 Nov; 50(11):1120-8. PubMed ID: 22024000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
    Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
    JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans.
    Mitchell SG; Gryczynski J; Schwartz RP; O'Grady KE; Olsen YK; Jaffe JH
    Drug Alcohol Depend; 2013 Mar; 128(3):222-9. PubMed ID: 22999817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
    Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
    JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim buprenorphine treatment in opiate dependence: A pilot effectiveness study.
    Abrahamsson T; Widinghoff C; Lilliebladh A; Gedeon C; Nilvall K; Hakansson A
    Subst Abus; 2016; 37(1):104-9. PubMed ID: 26176490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.